Posts by: Joana Carvalho

News

Multimodal analysis that incorporates data obtained from different methodologies seems to be the best approach to build a solid classification system for SCN1A genetic variants associated with Dravet syndrome, ... Read more

March 5, 2019March 5, 2019

Positive Outcomes can be Achieved Via Early Diagnosis, Adequate Treatment and Follow-up, Case Report Says

News

A deep understanding of the natural history of Dravet syndrome, an early diagnosis, carefully considered treatment, and regular follow-up care are crucial to attain positive clinical outcomes, according to a case ... Read more

February 19, 2019February 19, 2019

Latest Genetic Sequencing Techniques Reveal New Disease Mutations Associated With Epilepsy and Dravet Syndrome

News

Next-generation sequencing techniques have revealed that genetic mutations in the KCND3 gene may be responsible for more types of epilepsy than previously thought, and new candidate genes associated with Dravet syndrome have ... Read more

February 14, 2019February 19, 2019

Zogenix Submits Marketing Applictions for Fintepla to Treat Seizures in Dravet

News

Zogenix has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) and a Marketing Authorization Application (MAA) to the European Medicines Agency ... Read more

January 31, 2019January 31, 2019

SCN1A Mutations, Seizures Contribute to Disease Severity in Mouse Model of Dravet Syndrome

News

Mutations in the SCN1A gene and epileptic seizures contribute to disease severity in a mouse model of Dravet syndrome, a study reports. The study, “A two-hit story: Seizures and ... Read more

January 15, 2019January 15, 2019

Review Study Supports Ability of Epidiolex to Reduce Seizure Frequency in Dravet, Lennox-Gastaut Patients

News

GW Pharmaceuticals‘ Epidiolex, the first plant-derived cannabidiol medication to be approved by the U.S. Food and Drug Administration, is effective in significantly reducing the frequency of epileptic seizures as an ... Read more

December 13, 2018February 18, 2019

Fintepla Improves Behavioral and Emotional Control in Dravet Patients, Analysis of Phase 3 Trial Shows

News

Zogenix‘s investigational compound Fintepla (fenfluramine HCl oral solution) improves behavioral and emotional control in children and young adults with Dravet syndrome, according to recent data presented at the 72nd American Epilepsy Society ... Read more

November 29, 2018November 29, 2018

Diacomit Add-On Therapy More Effective in Children With Dravet Syndrome Who Carry Pathogenic SCN1A Mutations, Study Shows

News

Diacomit (stiripentol) add-on therapy is more effective in children with Dravet syndrome who have pathogenic (disease-causing) SCN1A mutations than in those with variants of unknown significance and benign SCN1A mutations, a ... Read more

October 18, 2018October 18, 2018

GABAergic System Impairment Worsens Seizures in Dravet Patients, Study Reveals

News

For the first time, researchers have described a dysfunction in the brain’s GABAergic system that could increase the frequency and severity of epileptic seizures in patients with Dravet syndrome. The ... Read more

September 27, 2018September 27, 2018

Glucose Uptake is Significantly Decreased in the Brains of Dravet Syndrome Children, Study Shows

News

For the first time, positron emission tomography (PET) scans revealed a significant decrease in the amount of glucose uptake in the brains of children with Dravet syndrome. Interestingly, this reduction ... Read more

Posts by: Joana Carvalho

Joana Carvalho

Multimodal Analysis is Best to Categorize SCN1A Genetic Variants, Study Says

Positive Outcomes can be Achieved Via Early Diagnosis, Adequate Treatment and Follow-up, Case Report Says

Latest Genetic Sequencing Techniques Reveal New Disease Mutations Associated With Epilepsy and Dravet Syndrome

Zogenix Submits Marketing Applictions for Fintepla to Treat Seizures in Dravet

SCN1A Mutations, Seizures Contribute to Disease Severity in Mouse Model of Dravet Syndrome

Review Study Supports Ability of Epidiolex to Reduce Seizure Frequency in Dravet, Lennox-Gastaut Patients

Fintepla Improves Behavioral and Emotional Control in Dravet Patients, Analysis of Phase 3 Trial Shows

Diacomit Add-On Therapy More Effective in Children With Dravet Syndrome Who Carry Pathogenic SCN1A Mutations, Study Shows

GABAergic System Impairment Worsens Seizures in Dravet Patients, Study Reveals

Glucose Uptake is Significantly Decreased in the Brains of Dravet Syndrome Children, Study Shows

Pin It on Pinterest